TARGET AUDIENCE
This educational activity is intended for physicians, nurse practitioners, and physician assistants in hematology as well as specialists in cardiology, neurology, nephrology, and other health care team members interested in learning about the various clinical trials for FXI/XIa inhibitors.

PROGRAM OVERVIEW
This webinar compares and contrasts the different clinical trials for FXI/XIa inhibitors (antisense oligonucleotides (ASOs) or small interfering RNA (siRNA), monoclonal antibodies (mAbs), small molecule FXI inhibitors), synthesize safety and efficacy results, and identify what is still unknown.

Upon completion of this activity, the learners should be able to:

• Explain how FXIa inhibitors may attenuate thrombosis without disrupting hemostasis
• Review the limitations of current therapies for secondary prevention in non-cardioembolic ischemic stroke
• Outline the limitations of antiplatelet therapy for the prevention of recurrent ischemic events in acute coronary syndrome

MODERATOR
Jeffrey Weitz, MD
Hematology
Professor of Medicine and Biochemistry and Biomedical Sciences
Hamilton Health Sciences and McMaster University
Hamilton, Ontario
Canada

FACULTY
Clay Johnston, MD, PhD
Neurologist
Chief Medical Officer/Co-Founder, Harbor Health
Adjunct Professor of Neurology, UCSF
San Francisco, California
USA

Rasha Al-Lamee, MD, PhD, BSc
Cardiologist
Consultant at Imperial College Healthcare NHS
Trust and Clinical Academic
Imperial College
London, England
United Kingdom

PLANNING COMMITTEE
Jeffrey Weitz, MD (Chair)
Hematology
Professor of Medicine and Biochemistry and Biomedical Sciences
Hamilton Health Sciences and McMaster University
Hamilton, Ontario
Canada

Rasha Al-Lamee, MD, PhD, BSc
Interventional Cardiology
Consultant at Imperial College Healthcare NHS
Trust and Clinical Academic
Imperial College
London, England
United Kingdom

María Cecilia Bahit, MD
Chief of Cardiology, Department INECO Neurociencias
Co-Chair, World Stroke Organization Heart and Brain Task Force
Rosario
Argentina

Jonathan Coutinho, MD, PhD, FESO
Amsterdam University Medical Centers
Department of Neurology
Amsterdam
The Netherlands

David Gailani, MD
Professor of Pathology, Microbiology, and Immunology
Ernest W. Goodpasture Chair in Experimental Pathology for Translational Research
Professor of Medicine
Nashville, Tennessee
USA

Clay Johnston, MD, PhD
Chief Medical Officer/Co-Founder, Harbor Health
Adjunct Professor of Neurology, UCSF
San Francisco, California
USA

Carolyn S.P. Lam, MD, PhD
Senior Consultant
Department of Cardiology and Director of Women's Heart Health
National Heart Centre Singapore
Duke-National University
Singapore

Tzu-Fei Wang, MD
Associate Professor, Division of Hematology
University of Ottawa
The Ottawa Hospital, General Campus
Ottawa, Ontario
Canada

Wolfgang C. Winkelmayer, MD, MPH, ScD, FASN
Gordon A. Cain Professor of Medicine
Chief, Section of Nephrology
Director, Selzman Institute for Kidney Health
Baylor College of Medicine
Houston, Texas
USA

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF and ISTH requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an independent educational grant from Bayer, Anthos, and the Bristol Myers Squibb and Johnson & Johnson Innovative Medicine Alliance (BMS/J&J Alliance).

The France Foundation and ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, ISTH, and the commercial supporter(s) assume no liability for the information herein.

Your registration, attendance at, and/or participation in this meeting constitutes consent to being photographed, videotaped, or recorded during the meeting by The France Foundation, its educational collaborators, or anyone authorized on behalf of these organizations. You further authorize, without any compensation paid to you, the use of any photographs, videos, or recordings that contain your likeness, image, or voice in any educational, informational, commercial, or promotional materials produced and/or distributed by The France Foundation, its educational collaborators, or anyone authorized by these organizations, as well as on any internet sites maintained by any of these entities. Images/recordings used for these purposes will not be sold, and no personal information about you or the subject (other than event location and date) will be included in the production of any material.